Whole-brain radiotherapy (WBRT) for brain metastases: Does the interval between imaging and treatment matter?

Heinke C. Hansen, Stefan Janssen, Cathrin Thieme, Aleksej Perlov, Steven E. Schild, Dirk Rades*

*Korrespondierende/r Autor/-in für diese Arbeit
    3 Zitate (Scopus)

    Abstract

    Background/Aim: Many patients with brain metastases receive whole-brain radiotherapy (WBRT). An important question is whether a delay between diagnosis of brain metastases and treatment impairs the patient’s prognosis. Patients and Methods: This retrospective study investigated the impact of the interval between diagnosis of brain metastases and WBRT plus ten additional factors on overall survival (OS) in 573 patients. Prospective trials cannot be performed due to ethical concerns. Results: On univariate analyses, age (p<0.001), performance status (p<0.001), controlled primary tumor (p=0.047), metastases outside the brain (p<0.001) and completion of WBRT (p<0.001) were associated with OS. The interval between diagnosis and WBRT had no significant impact (p=0.84). On multivariate analysis, age (p=0.047), performance status (p<0.001), metastases outside the brain (p=0.029) and completion of WBRT (p<0.001) maintained significance. Conclusion: WBRT may be postponed for good reasons (multidisciplinary coordination of treatment, missing histology). OS was significantly associated with previously identified factors, which demonstrates consistency of the present data.

    OriginalspracheEnglisch
    ZeitschriftAnticancer Research
    Jahrgang38
    Ausgabenummer12
    Seiten (von - bis)6835-6840
    Seitenumfang6
    ISSN0250-7005
    DOIs
    PublikationsstatusVeröffentlicht - 12.2018

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Whole-brain radiotherapy (WBRT) for brain metastases: Does the interval between imaging and treatment matter?“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Zitieren